These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7893446)

  • 21. Top AIDS researchers' strategy for antiretroviral treatment.
    AIDS Alert; 1996 Sep; 11(9):97-100. PubMed ID: 11363728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shedding of HIV-1 in semen during primary infection.
    Dyer JR; Gilliam BL; Eron JJ; Cohen MS; Fiscus SA; Vernazza PL
    AIDS; 1997 Mar; 11(4):543-5. PubMed ID: 9084808
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical response to dideoxyinosine in patients with HIV infection resistant to zidovudine.
    Bach MC
    N Engl J Med; 1990 Jul; 323(4):275. PubMed ID: 2114544
    [No Abstract]   [Full Text] [Related]  

  • 25. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
    Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.
    Yerly S; Denereaz N; Mermillod B; Hirschel B; Perrin L
    Antivir Ther; 1996 Aug; 1(3):167-71. PubMed ID: 11322250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.
    Rusconi S; La Seta Catamancio S; Citterio P; Bulgheroni E; Kurtagic S; Galazzi M; Croce F; Moroni M; Galli M
    Antivir Ther; 2001 Mar; 6(1):41-6. PubMed ID: 11417760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.
    Yerly S; Rutschmann OT; Opravil M; Marchal F; Hirschel B; Perrin L
    J Infect Dis; 1999 Sep; 180(3):850-3. PubMed ID: 10438378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antiretroviral treatment. Present and future of the combinations].
    Gatell-Artigas JM
    Rev Neurol; 1996 Dec; 24(136):1627-31. PubMed ID: 9064189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continued zidovudine or didanosine for human immunodeficiency virus infection.
    Behrman RE; Kammerman LA; Feigal DW
    N Engl J Med; 1992 Nov; 327(22):1598-9. PubMed ID: 1435893
    [No Abstract]   [Full Text] [Related]  

  • 31. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
    Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U
    AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263
    [No Abstract]   [Full Text] [Related]  

  • 32. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
    Rubio A; Gómez-Cano M; Puig T; Leal M; Pérez-Olmeda M; Ruiz L; Clotet B; Rey C; Zamora L; Xaus N; Soriano V
    Antivir Ther; 1999; 4(1):45-9. PubMed ID: 10682128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients].
    Reynes J; Montes B; Delmas B; Vendrell JP; Janbon F; Segondy M
    Pathol Biol (Paris); 1997 May; 45(5):441-4. PubMed ID: 9296101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine].
    Gómez-Cano M; Soriano V; García-Lerma G; González-Lahoz J
    An Med Interna; 1998 Mar; 15(3):145-7. PubMed ID: 9567422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine.
    Koot M; Schellekens PT; Mulder JW; Lange JM; Roos MT; Coutinho RA; Tersmette M; Miedema F
    J Infect Dis; 1993 Sep; 168(3):733-6. PubMed ID: 8102631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in biologic phenotype of human immunodeficiency virus during treatment of patients with didanosine.
    Zheng NN; McQueen PW; Hurren L; Evans LA; Law MG; Forde S; Barker S; Cooper DA; Delaney SF
    J Infect Dis; 1996 May; 173(5):1092-6. PubMed ID: 8627059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continued zidovudine or didanosine for human immunodeficiency virus infection.
    Saitz R; Friedmann PD; Roberts MS
    N Engl J Med; 1992 Nov; 327(22):1598; author reply 1599. PubMed ID: 1435891
    [No Abstract]   [Full Text] [Related]  

  • 38. Approval for broader use of DDI.
    Am Fam Physician; 1992 Dec; 46(6):1841-2. PubMed ID: 1456202
    [No Abstract]   [Full Text] [Related]  

  • 39. AIDS dementia complex and didanosine.
    Portegies P; Enting RH; de Jong MD; Danner SA; Reiss P; Goudsmit J; Lange JM
    Lancet; 1994 Sep; 344(8924):759. PubMed ID: 7915809
    [No Abstract]   [Full Text] [Related]  

  • 40. From the National Institutes of Health.
    Healy B
    JAMA; 1992 Mar; 267(10):1319. PubMed ID: 1740841
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.